Cardiff Oncology Inc (CRDF)

NASDAQ

Currency in USD

2.590

-0.070(-2.63%)

Closed03/12

Pre Market

2.600+0.010(+0.39%)

08:00:01

Fair Value

Day's Range

2.535

2.680

52 wk Range

1.210

6.420

CRDF Income Statement

Explore the detailed Cardiff Oncology Inc income statement, offering a comprehensive view of the company’s financial performance. Review essential metrics such as revenue, gross profit, operating income, and net income over selected periods. This page provides a clear breakdown of profitability and operational efficiency, helping you evaluate Cardiff Oncology Inc's growth trends and overall financial health.

Advanced Income Statement

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Total Revenues

0.24

0.37

0.36

0.39

0.49

Total Revenues Growth

-35.34%

+49.61%

-1.91%

+7.52%

+26.42%

Cost Of Revenues

11.16

11.24

17.38

27.11

32.86

Gross Profit

-10.92

-10.87

-17.02

-26.72

-32.37

Gross Profit Growth

-30.23%

+0.45%

-56.56%

-57.03%

-21.14%

Gross Profit Margin %

-4,462.87%

-2,969.67%

-4,740.11%

-6,922.54%

-6,632.99%

Other Operating Expenses, Total

5.76

8.22

11.84

13.18

13.04

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-28.04%	+42.63%	+44.07%	+11.34%	-1.05%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	5.76	8.22	11.84	13.18	13.04
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-

Operating Income

-16.68

-19.09

-28.86

-39.9

-45.41

Operating Income Growth

-1.77%

-14.43%

-51.18%

-38.28%

-13.81%

EBIT Margin %

-6,817.79%

-5,214.75%

-8,037.6%

-10,337.31%

-9,305.74%

Net Interest Expenses

0.23

0.09

0.26

1.58

4.07

Net Interest Expenses Growth

+20.69%

-62.42%

+200%

+498.86%

+157.37%

Interest Expense, Total

-

-0

-

-

-

Interest And Investment Income

0.23

0.09

0.26

1.58

4.07

Other Non Operating Expenses, Total

0.03

-0.31

0.3

-0.38

-0.1

EBT, Excl. Unusual Items

-16.41

-19.31

-28.29

-38.7

-41.44

Gain (Loss) On Sale Of Assets

-

-

-

-

-

Other Unusual Items, Total

-

-

-

-

-

EBT, Incl. Unusual Items

-16.41

-19.31

-28.29

-38.7

-41.44

EBT, Incl. Unusual Items Growth

+0.29%

-17.62%

-46.53%

-36.81%

-7.07%

EBT, Incl. Unusual Items Margin

-6,709.74%

-5,275.14%

-7,880.5%

-10,026.94%

-8,492.01%

Income Tax Expense

-

-

-

-

-

Net Income to Company

-16.41

-19.31

-28.29

-38.7

-41.44

Minority Interest

-

-

-

-

-

Net Income

-16.41

-19.31

-28.29

-38.7

-41.44

Net Income Growth

+0.29%

-17.62%

-46.53%

-36.81%

-7.07%

Net Income Margin %

-6,709.74%

-5,275.14%

-7,880.5%

-10,026.94%

-8,492.01%

Preferred Dividend and Other Adjustments

0.29

3.29

0.02

0.02

0.02

Net Income to Common Excl. Extra Items

-16.71

-22.6

-28.32

-38.73

-41.47

Basic EPS - Continuing Operations

-2.8

-1.08

-0.73

-0.89

-0.93

Basic EPS - Continuing Operations Growth

+66.16%

+61.29%

+32.98%

-22.44%

-4.49%

Diluted EPS - Continuing Operations

-2.8

-1.08

-0.73

-0.89

-0.93

Diluted EPS - Continuing Operations Growth

+66.16%

+61.29%

+32.98%

-22.68%

-4.49%

Basic Weighted Average Shares Outstanding

5.97

20.88

39.03

43.6

44.68

Diluted Weighted Average Shares Outstanding

5.97

20.88

39.03

43.6

44.68

Dividend Per Share

-

-

-

-

-

Dividend Per Share Growth

-

-

-

-

-

EBITDA

-16.18

-18.62

-28.4

-39.67

-45.01

EBITDA Growth

-4.22%

-15.05%

-52.55%

-39.65%

-13.48%

EBITDA Margin %